Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
New hope for liver cancer patients with cirrhosis: safety trial launches
Disease control Recruiting nowThis study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New cancer drug combo enters first human tests
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. Ab…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called GDC-7035, designed to target cancers with a specific genetic change called KRAS G12D. The trial includes about 410 adults with advanced solid tumors that have not responded to other treatments. Researchers will give the drug alone or with other …
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for ulcerative colitis patients who failed other treatments
Disease control Recruiting nowThis study tests a new drug called RO7837195 for people with moderate to severe ulcerative colitis who haven't gotten better with other treatments. About 224 participants will receive either the drug or a placebo for 12 weeks to see if it can bring about remission. The goal is to…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Cell therapy trial aims to halt vision loss in dry AMD
Disease control Recruiting nowThis study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The m…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New eye drug combo aims to tackle Diabetes-Related vision loss
Disease control Recruiting nowThis early-stage trial tests an experimental drug called RO7823653, given as an eye injection alone or with an approved drug (faricimab), for people with diabetic macular edema—a condition where diabetes causes fluid buildup and vision loss in the center of the eye. The study wil…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced breast cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called GDC-4198, alone or combined with another drug (giredestrant), against a standard treatment (abemaciclib plus giredestrant) in people with advanced ER+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. The trial has two …
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced prostate cancer: experimental drug enters human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New daily pill for breast cancer now available through early access program
Disease control AVAILABLEThis expanded access program provides giredestrant, a daily oral drug, to people with ER-positive, HER2-negative breast cancer (early or advanced) who have limited treatment options. The goal is to offer early access before the drug is commercially available in the US. Participan…
Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for advanced prostate cancer: experimental drug GDC-1261 enters trials
Disease control Recruiting nowThis study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New eye implant for wet AMD under safety spotlight
Disease control Recruiting nowThis study is testing a refillable eye implant that delivers the drug ranibizumab to treat wet age-related macular degeneration (AMD). The main goal is to see if the implant affects the cells on the inner surface of the cornea. About 188 people with wet AMD will receive the impla…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New triple therapy aims to stop pancreatic Cancer's return after surgery
Disease control Recruiting nowThis Phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) and an immunotherapy drug (atezolizumab) to standard chemotherapy (mFOLFIRINOX) can keep pancreatic cancer from coming back after surgery. About 260 people whose tumors were completely remo…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to quiet artery inflammation and prevent heart attacks
Disease control Recruiting nowThis study tests a drug called selnoflast in 162 people with atherosclerosis (hardened arteries) who are at high risk for heart attacks or strokes. The goal is to see if selnoflast can reduce inflammation inside the arteries, measured by a special PET scan, compared to a placebo.…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for lung cancer: personalized drug cocktails before surgery
Disease control Recruiting nowThis study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control Recruiting nowThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for advanced breast cancer: experimental drug targets resistant tumors
Disease control Recruiting nowThis early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New inhaled drug hopes to clear lungs in mucus diseases
Symptom relief Recruiting nowThis early-stage study tests an inhaled drug called GDC-6988 in people with lung conditions that cause thick mucus, like non-CF bronchiectasis and COPD. The main goal is to check if the drug is safe and tolerable. About 128 adults with stable disease and good lung function will t…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New drug RO7875913 tested in healthy volunteers for first time
Knowledge-focused Recruiting nowThis early-stage trial is testing a new drug called RO7875913 in 40 healthy volunteers to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo. The study aims to find the right dose for future trials, but offers no direct treatme…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New registry aims to uncover risks of common transplant drug in pregnancy
Knowledge-focused Recruiting nowThis registry follows pregnant women who have taken mycophenolate, a drug used to prevent organ rejection and treat autoimmune diseases. Researchers will collect data on pregnancy complications and birth defects up to one year after birth. The goal is to better understand the dru…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver function may change how inavolisib works
Knowledge-focused Recruiting nowThis early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver pro…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC